THE EVALUATION OF MTOR PATHWAY DYSREGULATION AS A NOVEL BLOOD‐BASED PHENOTYPIC RISK BIOMARKER FOR THE ASSESSMENT OF ALZHEIMER'S DISEASE AND DEMENTIA. (1st July 2014)